Trusted by over 1.2 Million Global Healthcare Seekers

EpiPen Outrage: Mylan Steps Up and Takes the Heat


Mylan, the drug manufacturing company behind the recent EpiPen outrage, has announced its plan to reduce the cost of the medical device amidst a backlash of public scorn. A steep rise in the price of EpiPens—nearly 700 percent in the past six years—has left millions of Americans struggling to afford the life-saving devices.

The announcement came Wednesday after Hillary Clinton publically criticized the company and the Federal Trade Commission threatened to launch an investigation into the drug maker’s possible violation of antitrust laws through price-hiking.

Other prominent members of the community also voiced concern over the recent EpiPen outrage, including Minnesota Senator, Amy Klobuchar, whose daughter carries the emergency medical device in the event of a life-threatening allergic reaction. In a recent interview with CNN, Klobuchar said, “What this company’s done is taken a product that in 2009 was about $100 and moved it up to this year between $500 and $600. [EpiPens] reach their expiration date in one year so then you have to buy more.”

The backlash against Mylan gained significant traction after it was confirmed the devices were being sold in Canada for hundreds of dollars less than in the U.S. Also fueling the EpiPen outrage was Mylan’s decision to continually increase the cost of the devices without making any significant improvements to them, as well as the dramatic increase in the annual salaries of the company’s top executives following the EpiPen price increases.

In Wednesday’s press release, Mylan addressed the public outcry by saying it would provide several different options for patients who can’t afford the cost of EpiPens. Mylan’s options include an instant savings card of $300 that would reduce the cost of the device up to 50 percent, an expanded financial assistance plan that would include a family of four with an annual income of $97,200 or less, and a “consumer direct plan” that would allow the company to sell the device directly to patients at a lower cost.

The recent EpiPen outrage also prompted Mylan to emphasis that it will continue providing select school systems with free EpiPens and that it will still permit financially eligible families to receive a two-pack of EpiPens for free.

EpiPens provide life-saving epinephrine that helps relax the airway muscles of individuals with severe allergic reactions.

Photo Credit:  a katz /

Learn about how you can become a Certified Medical Tourism Professional→
Disclaimer: The content provided in Medical Tourism Magazine ( is for informational purposes only and should not be considered as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. We do not endorse or recommend any specific healthcare providers, facilities, treatments, or procedures mentioned in our articles. The views and opinions expressed by authors, contributors, or advertisers within the magazine are their own and do not necessarily reflect the views of our company. While we strive to provide accurate and up-to-date information, We make no representations or warranties of any kind, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained in Medical Tourism Magazine ( or the linked websites. Any reliance you place on such information is strictly at your own risk. We strongly advise readers to conduct their own research and consult with healthcare professionals before making any decisions related to medical tourism, healthcare providers, or medical procedures.
Free Webinar: Building Trust, Driving Growth: A Success Story in Medical Travel Through Exceptional Patient Experiences